Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS (2025)
Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia
Clin Cancer Res (in press)
DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050

Wei Q, Foyn H, Landskron J, Wang S, Rye IH, Skånland SS, Russnes HEG, Klaveness J, Ahmad R, Taskén K (2025)
Identification of a group of 9-amino-acridines that selectively downregulate regulatory T cell functions through FoxP3
iScience, 28 (3), 111931
DOI 10.1016/j.isci.2025.111931, PubMed 40034859

Arseni L, Sigismondo G, Yazdanparast H, Hermansen JU, Mack N, Ohl S, Kalter V, Iskar M, Kalxdorf M, Friedel D, Rettel M, Paul Y, Ringshausen I, Eldering E, Dubois J, Kater AP, Zapatka M, Roessner PM, Tausch E, Stilgenbauer S, Dietrich S, Savitski MM, Skånland SS, Krijgsveld J, Lichter P et al. (2025)
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
Nat Commun, 16 (1), 1041
DOI 10.1038/s41467-025-56318-7, PubMed 39863584